AU7872491A - Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs - Google Patents
Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugsInfo
- Publication number
- AU7872491A AU7872491A AU78724/91A AU7872491A AU7872491A AU 7872491 A AU7872491 A AU 7872491A AU 78724/91 A AU78724/91 A AU 78724/91A AU 7872491 A AU7872491 A AU 7872491A AU 7872491 A AU7872491 A AU 7872491A
- Authority
- AU
- Australia
- Prior art keywords
- salicylate
- inflammatory drugs
- nonsteroidal anti
- lipid prodrugs
- prodrugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000002632 lipids Chemical class 0.000 title 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 title 1
- 229960001860 salicylate Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51960090A | 1990-05-07 | 1990-05-07 | |
| US519600 | 1990-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU7872491A true AU7872491A (en) | 1991-11-27 |
Family
ID=24069000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU78724/91A Abandoned AU7872491A (en) | 1990-05-07 | 1991-04-10 | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU7872491A (en) |
| WO (1) | WO1991016920A1 (en) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0560900T3 (en) * | 1990-12-03 | 1995-05-08 | Nexstar Pharmaceuticals Inc | Prevention of synovial adhesions |
| IL105244A (en) * | 1993-03-31 | 2003-07-31 | Dpharm Ltd | Prodrugs with enhanced penetration into cells |
| US6413949B1 (en) | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
| US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
| FR2714382B1 (en) * | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipids vector of active molecule, their preparation and their use in cosmetic or dermatological compositions. |
| US5763422A (en) * | 1995-01-27 | 1998-06-09 | Board Of Regents, The University Of Texas System | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| US6313106B1 (en) | 1995-06-07 | 2001-11-06 | D-Pharm Ltd. | Phospholipid derivatives of valproic acid and mixtures thereof |
| US7517858B1 (en) * | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
| DK0831852T3 (en) | 1995-06-07 | 2007-03-19 | Univ Emory | Nucleosides with anti-hepatitis B virus activity |
| AUPN766496A0 (en) * | 1996-01-22 | 1996-02-15 | University Of New England, The | Method and composition for the potentiation of anti-inflammatory drugs |
| US6030997A (en) * | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
| MXPA00008348A (en) | 1998-02-25 | 2005-07-15 | Univ Emory | 2'-fluoronucleosides. |
| WO2000009531A2 (en) | 1998-08-10 | 2000-02-24 | Novirio Pharmaceuticals Limited | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B |
| US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
| DE69923338T2 (en) | 1998-11-02 | 2006-04-06 | Gilead Sciences, Inc., Foster City | COMBINATION THERAPY FOR THE TREATMENT OF HEPATITIS B INFECTIONS |
| IL127143A0 (en) | 1998-11-19 | 1999-09-22 | Dpharm Ltd | Phospholipid terivatives of non-steroidal anti inflammatory drugs |
| IL131887A0 (en) | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
| KR20080059679A (en) | 2000-03-29 | 2008-06-30 | 조지타운 유니버시티 | Treatment of Delta Hepatitis Virus Infection |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| IL153020A0 (en) | 2000-05-26 | 2003-06-24 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
| US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US20030087873A1 (en) | 2000-10-18 | 2003-05-08 | Lieven Stuyver | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
| KR20040002871A (en) | 2001-03-01 | 2004-01-07 | 트라이앵글 파마슈티칼스 인코포레이티드 | Polymorphic and other crystalline forms of cis-ftc |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| BR0312278A (en) | 2002-06-28 | 2007-06-19 | Idenix Cayman Ltd | 2'-c-methyl-3'-o-1-valine ribofuranosyl cytidine ester for treatment of flaviviridae infections |
| MY140819A (en) | 2002-06-28 | 2010-01-29 | Idenix Caymans Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| TWI244393B (en) | 2002-08-06 | 2005-12-01 | Idenix Pharmaceuticals Inc | Crystalline and amorphous forms of beta-L-2'-deoxythymidine |
| HUE027522T2 (en) | 2002-09-13 | 2016-11-28 | Novartis Ag | Beta-l-2'-deoxynucleosides for use in the treatment of resistant hbv strains |
| BR0316363A (en) | 2002-11-15 | 2005-10-04 | Idenix Cayman Ltd | 2'-branched nucleosides and flaviviridae mutation |
| EP2319853B1 (en) | 2002-12-12 | 2014-03-12 | IDENIX Pharmaceuticals, Inc. | Process for the production of 2'-branched nucleosides |
| PL3521297T3 (en) | 2003-05-30 | 2022-04-04 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
| BRPI0412849A (en) | 2003-07-25 | 2006-09-26 | Idenix Cayman Ltd | compounds, compositions and uses of purine nucleoside analogues for the treatment of flaviviridae, including hepatitis c |
| DK2574341T3 (en) | 2004-03-29 | 2017-06-26 | Univ South Florida | Effective treatment of tumors and cancer with triciribin phosphate |
| CN101023094B (en) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
| PT3109244T (en) | 2004-09-14 | 2019-06-04 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| WO2007038507A2 (en) | 2005-09-26 | 2007-04-05 | Pharmasset, Inc. | Modified 4'-nucleosides as antiviral agents |
| US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
| PT2081929E (en) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP3042660A3 (en) | 2008-04-15 | 2016-10-26 | RFS Pharma, LLC. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| NZ593648A (en) | 2008-12-23 | 2013-09-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| NZ617066A (en) | 2008-12-23 | 2015-02-27 | Gilead Pharmasset Llc | Nucleoside analogs |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
| ES2644990T3 (en) | 2010-03-31 | 2017-12-01 | Gilead Pharmasset Llc | Stereoselective synthesis of active ingredients that contain phosphorus |
| PT3042910T (en) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-spiro-nucleosides for use in the therapy of hepatitis c |
| US20130244982A1 (en) | 2010-12-02 | 2013-09-19 | Bengurion University Of The Negev Research And Development Authority | Conjugates of a phospholipid and a drug for the treatment of inflammatory bowel disease |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| NZ716840A (en) | 2013-08-27 | 2017-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| PL240299B1 (en) * | 2017-06-22 | 2022-03-14 | Wrocław University Of Environmental And Life Sciences | Phosphatidylcholines and method for obtaining them |
| PL240436B1 (en) * | 2017-06-22 | 2022-04-04 | Wrocław University Of Environmental And Life Sciences | 2-Hydroxyphosphatidyl cholines and method for obtaining them |
| PL240437B1 (en) * | 2017-06-22 | 2022-04-04 | Wrocław University Of Environmental And Life Sciences | Phosphatidylcholines and method for obtaining them |
| PL238967B1 (en) * | 2017-06-22 | 2021-10-25 | Wrocław University Of Environmental And Life Sciences | The method of obtaining phosphatidylcholine containing ibuprofen in the sn-2 position and the fatty acid residue in the sn-1 position |
| CN112437674A (en) * | 2018-04-11 | 2021-03-02 | 新墨西哥科技大学研究园公司 | Lipid prodrugs for drug delivery |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3644424A (en) * | 1969-10-16 | 1972-02-22 | Schering Corp | Glyceryl acetylsalicylate and its analgesic anti-inflammatory use |
| US3746728A (en) * | 1971-09-10 | 1973-07-17 | Smith Kline French Lab | Phosphatide derivatives of prostaglandins |
| US3988446A (en) * | 1974-11-07 | 1976-10-26 | Abbott Laboratories | Glycerides with anti-inflammatory properties |
| DE2629135A1 (en) * | 1976-06-29 | 1978-01-12 | Nattermann A & Cie | NEW PHOSPHOLIPID DERIVATIVES OF PROSTAGLANDINES AND THE METHOD FOR THEIR PRODUCTION |
-
1991
- 1991-04-10 WO PCT/US1991/002447 patent/WO1991016920A1/en not_active Ceased
- 1991-04-10 AU AU78724/91A patent/AU7872491A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1991016920A1 (en) | 1991-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU7872491A (en) | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs | |
| AU1579092A (en) | Anti-infective and anti-inflammatory releasing systems for medical devices | |
| ZA882957B (en) | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal anti-inflammatory drugs | |
| FI935380L (en) | Medicinal products containing S(+)-ibuprofen | |
| AU1081292A (en) | New beta-amino- alpha-hydroxycarboxylic acids and their use | |
| NZ236985A (en) | 3-carboxy and thiocarboxy-4-isoxazolecarboxamide ester derivatives; preparation and pharmaceutical preparation | |
| AU2111095A (en) | Salts of omega-3-polyunsaturated fatty acids and pharmaceutical formulations containing them | |
| AU1788992A (en) | Display unit and light box therefor | |
| AU3720193A (en) | Hydroisoindolines and hydroisoquinolines as psychotropic drugs | |
| HU00207A9 (en) | Sulfonanilide derivatives and medicine | |
| AU1846488A (en) | Analgesic and anti-inflammatory thiourea derivatives | |
| AU1424292A (en) | A new and improved internally illuminated sign | |
| AU7543887A (en) | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs | |
| AU1766592A (en) | Pharmaceutical formulations of a benzodiazepine | |
| AU2409992A (en) | Carcinostatic compound and production thereof | |
| AU3815495A (en) | Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects | |
| AU1740292A (en) | Triphenylethylene derivative and pharmaceutical preparation containing the same | |
| AU5560694A (en) | Pharmaceutical formulations of ibuprofen | |
| AU4419293A (en) | Pharmaceutical compositions having antiaggregant and vasodilating activities | |
| AU1670895A (en) | Pharmaceutical product comprising a salicylate of an esterifiable beta-blocker | |
| AU3363193A (en) | Pharmaceutical formulations comprising a clavulanic acid salt and erithromycin derivative | |
| AU7468291A (en) | Lipid fractionation and products so obtained | |
| AU1450788A (en) | Thiophene-2-carbox-amide derivatives and their pharmaceutical use | |
| AU655843B2 (en) | Blood lipid metabolism ameliorant | |
| AU7551896A (en) | 1-azabicycloheptane derivatives and their pharmaceutical use |